Posted by Michael Wonder on 16 Dec 2021
Apellis and Sobi Announce EU approval of Aspaveli (pegcetacoplan) for treatment of PNH
15 December 2021 - The first targeted C3 therapy approved in the EU.
Apellis Pharmaceuticals and Swedish Orphan Biovitrum announced today that the European Commission has approved Aspaveli (pegcetacoplan), the first and only targeted C3 therapy, for the treatment of adults with paroxysmal nocturnal hemoglobinuria who are anaemic after treatment with a C5 inhibitor for at least three months.
